Life sciences lab real estate is rebounding from disaster

Key Points:

• Life science laboratory demand, particularly in biotech and biopharma, dropped significantly last year due to severe NIH funding cuts, leading to a 27.4% vacancy rate in major markets like Boston and the Bay Area.
• The sector is beginning to stabilize with increased venture capital investment and the lowest new construction levels since 2017, but JLL forecasts a gradual market recovery driven by supply reduction rather than demand growth.
• The oversupply issue is compounded by a shift in how life sciences companies use real estate, influenced by advancements in AI, automation, and robotics, which are transforming lab operations and space requirements.
• Architectural firm Gensler highlights that many vacant labs were never true "Class A" spaces, and future success depends on adapting facilities to new technologies, including upgrading infrastructure to support AI, robotics, and increased power needs.
• Collaboration between scientists, AI researchers, and engineers is reshaping lab environments, with companies like Genentech investing billions to modernize and consolidate R&D spaces that support interdisciplinary work and advanced technologies.